Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
POZEN Reports Third Quarter 2009 Results
POZEN Names Elizabeth A. Cermak As Executive Vice President, Chief Commercial Officer
POZEN Reports Second Quarter 2009 Results
POZEN To Present at the 2009 BMO Capital Markets Focus on Healthcare Conference
POZEN Announces July 28, 2009 Webcast of Second Quarter 2009 Results
POZEN Submits New Drug Application For VIMOVO™ (PN 400)
POZEN Announces Election of Angela M. Larson to Board of Directors
POZEN Receives Decision From AstraZeneca to File PN 400 NDA
POZEN Reports First Quarter 2009 Results
POZEN Announces April 30, 2009 Webcast of First Quarter 2009 Results
POZEN To Present at the Citi Annual Biotech Day
POZEN to Present at the Cowen and Company 29th Annual Healthcare Conference
Zacks Analyst Blog Highlights: Pozen, Inc., GlaxoSmithKline, AstraZeneca, Grupo Aeroportuario Del Sureste and Citigroup
Zacks Bull & Bear of the Day Highlights: Pozen Inc., First Advantage Corp., Agrium, CF Industries and Terra Industries
POZEN Reports Fourth Quarter and Year End 2008 Results
POZEN Announces February 25, 2009 Webcast of Fourth Quarter and Year End 2008 Results
POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint
POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 Trials
POZEN To Participate in The RBC Capital Markets 2008 Healthcare Conference
POZEN'S PA32520 Study Data Demonstrated Better Upper Gastrointestinal Protection
POZEN Reports Third Quarter 2008 Results
POZEN Announces October 29, 2008 Webcast of Third Quarter 2008 Results
POZEN Confirms ANDA Filing for Treximet(R) Tablets
POZEN Informed of FDA Internal Review of Gastric Ulcers as a Primary Endpoint in Clinical Trials
POZEN To Present at The UBS Life Sciences Conference
POZEN Sponsors Habitat for Humanity Home in Hillsborough, North Carolina
POZEN To Present at the 3rd Annual Citi Biotech Day
POZEN Receives Initial FDA Response To PA32540 SPA
POZEN Reports Second Quarter 2008 Results
POZEN to Present at the 2008 BMO Capital Markets Focus on Healthcare Conference
POZEN Announces July 29, 2008 Webcast of Second Quarter 2008 Results
POZEN To Present at the Jefferies 2nd Annual Healthcare Conference
POZEN Demonstrates Bioequivalence to Enteric Coated Aspirin for PA32540
POZEN To Present at the Seventh Annual Needham & Co., LLC Biotechnology & Medical Technology Conference
POZEN Announces PN 200 Podium Presentation at Digestive Disease Week - May 27 2008 12:56AM
POZEN To Present at the Citigroup Global Healthcare Conference - May 27 2008 12:53AM
POZEN IND and NDA for Treximet(TM) (Sumatriptan/Naproxen Sodium) Transferred to GlaxoSmithKline - Jun 2 2008 1:51AM
POZEN Reports First Quarter 2008 Results - Jun 2 2008 1:51AM
POZEN To Present at Baird's 2008 Growth Stock Conference - Jun 2 2008 1:51AM
POZEN Announces Receipt of $20 Million in Milestone Payments from GlaxoSmithKline
POZEN Announces May 8, 2008 Webcast of First Quarter 2008 Results
BellwetherReport.com Initiates Analyst Coverage on LLTC, INTC, SSCC and POZN
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
